论文部分内容阅读
目的:观察糖肾Ⅰ号方对早期糖尿病肾病大鼠的干预作用及对周期蛋白P27表达的影响,分析其可能的作用机制。方法:通过单侧肾切除合并注射链脲佐菌素(STZ)建立早期糖尿病肾病大鼠模型,随机分为假手术组(SO)、模型对照组(M)、糖肾Ⅰ号组(TS)、洛汀新组(B)、糖洛合组(TS+B),共5组,各10只。模型成功后给予不同的干预,共8周,末次给药12小时后,采集尿液、血液标本检测,组织行免疫组化检测,观察各组大鼠的肾重、肾脏肥大指数、肌酐,尿素氮等生化指标及P27蛋白表达的变化。结果:与模型组比较,糖肾Ⅰ号治疗组肾重、肾脏肥大指数明显下降,血清Scr、BUN显著降低,P27表达明显下调(P<0.05)。与洛汀新组比较,无明显差异,治疗组比较,以糖洛合组疗效最好。结论:糖肾Ⅰ号疗效确切,其作用机制可能部分通过下调P27的表达抑制肾脏肥大,从而发挥肾脏保护作用,与洛汀新合用在改善肾功能方面具有协同作用。
Objective: To observe the effect of Tangshen No. 1 on the early diabetic nephropathy rats and its effect on the expression of cyclin P27, and to analyze its possible mechanism. Methods: A rat model of early diabetic nephropathy was established by unilateral nephrectomy combined with streptozotocin (STZ) and randomly divided into sham operation group (SO), model control group (M), Tangshen Ⅰ group (TS) , Lotensin group (B), Luo Luo group (TS + B), a total of 5 groups, each 10. The model was given different interventions after successful, a total of 8 weeks. After the last administration for 12 hours, urine and blood samples were taken for detection. Immunohistochemistry was performed to observe the changes of renal weight, renal hypertrophy index, creatinine, urea Nitrogen and other biochemical indicators and P27 protein expression changes. Results: Compared with the model group, the renal weight and renal hypertrophy index of Tangshen Ⅰ treatment group were significantly decreased, while the levels of Scr and BUN were significantly decreased and the expression of P27 was significantly decreased (P <0.05). And Lotensin new group, no significant difference in the treatment group, the best effect with the sugar Luohe group. CONCLUSION: Tangshen Ⅰ has definite curative effect. Its mechanism of action may partly inhibit renal hypertrophy by down-regulating the expression of P27, thereby exerting a protective effect on the kidney and synergizing with Lotensin in improving renal function.